BACKGROUND

- Both angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) have demonstrated kidney-protective effects in diabetes, and are also effective in treating hypertension (in patients with diabetes and hypertension, therapy should include an ACE-I/ARB, as long as one is tolerated).
  - ACE-I (and in some cases, ARBs) have been shown to improve cardiovascular and renal outcomes via effects that are independent of blood-pressure reduction.
  - Blood-pressure goal for patients with diabetes is <140/90.

- The Centers for Medicare and Medicaid Services (CMS) have incorporated appropriate treatment of patients with diabetes and hypertension into their Medicare Part D Health and Drug Plan Quality and Performance Ratings (STAR ratings).
- To assist payers in improving the quality of care delivered to their beneficiaries, Magellan Rx Management has developed and implemented a Diabetes Treatment Clinical Program designed to specifically address the quality standards incorporated into the CMS Star Rating Measure D10, Diabetes Treatment Clinical Program designed to specifically address the quality standards incorporated into the CMS Star Rating Measure D10.
- The Diabetes Treatment Clinical Program was recommended using an ACE-I/ARB/DRI when appropriate.

OBJECTIVE

To measure the impact of a clinical program on measure D10—the proportion of patients with diabetes and hypertension on ACE-I/ARB/DRI therapy within a regional Medicare health plan.

METHODS

- The Diabetes Treatment Measure population consists of all members who have filled a diabetes and hypertension medication between January and December 2014.

- Members are considered compliant when their hypertension agent is an ACE-I/ARB/DRI and non-compliant when not receiving an ACE-I/ARB/DRI.
  - The treatment rate is calculated by taking the numerator (compliant members) divided by the denominator (compliant + non-compliant members).
  - A clinical program was implemented to increase the treatment rate, which was to be accomplished through telephonic outreach by clinical staff to providers, pharmacies, and patients.

- The focus of this outreach was recommending use of an ACE-I/ARB/DRI, when appropriate.

RESULTS

Table 1. Outreach Status of Non-Compliant Members

<table>
<thead>
<tr>
<th>Status</th>
<th>Member Count</th>
<th>Member Count %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment Measure Population</td>
<td>4,149</td>
<td>100%</td>
</tr>
<tr>
<td>Outreach Population</td>
<td>963</td>
<td>23%</td>
</tr>
<tr>
<td>Conversions to ACE-I/ARB/DRI</td>
<td>391</td>
<td>9.4%</td>
</tr>
<tr>
<td>Clinical &amp; Non-Clinical Rationale for Non-Compliance</td>
<td>257</td>
<td>6.2%</td>
</tr>
</tbody>
</table>

Figure 1. Treatment Rate vs. Projected Rate without Conversions

- Between January and December 2014, a Diabetes Treatment Clinical Program utilizing clinical outreach resulted in a treatment rate of 88.1% (4 stars) for a regional Medicare health plan, representing a 4.5% increase compared to the same time period in 2013.

- 391 resulted in a claim for an ACE-I/ARB/DRI.

- 257 resulted in clinical and non-clinical rationale for non-compliance.

- Without successful conversions (members with an ACE-I/ARB/DRI claim after outreach), the treatment rate would have been as low as 73.9% (1 star).

- The most common reasons patients in the Diabetes Treatment population did not receive an ACE-I/ARB/DRI were renal complications (35%), patient was not diabetic or not hypertensive (28%), patient had an allergy/intolerance to the medication (28%), and patient refused (11%).

- It has been estimated that a cumulative, overall 1-star improvement across all measurements (from 5 to 4) is worth $50 per member per month.

Figure 2. Unsuccessful Reason Types

- Clinical outreach to non-compliant members and their associated providers and pharmacies resulted in a 2-star improvement for the Diabetes Treatment Measure and prevented a 2-star decrease.

- Treatment rate in a health plan utilizing a Diabetes Treatment Clinical Program increased by 4.5% from 2013 to 2014 compared to the national average of 0.8%.

- Many patients did not use ACE-I/ARB/DRI due to clinically valid reasons. These include renal complications, not having diabetes and/or hypertension, and allergies/intolerances. Clinical interventions focusing on improving this measure should take these situations into account to ensure patients are receiving appropriate medications.

Figure 3. Treatment Rate Improvements vs. MAPD National Avg.

- Clinical outreach to non-compliant members and their associated providers and pharmacies resulted in a 2-star improvement for the Diabetes Treatment Measure and prevented a 2-star decrease.

- Treatment rate in a health plan utilizing a Diabetes Treatment Clinical Program increased by 4.5% from 2013 to 2014 compared to the national average of 0.8%.

- Many patients did not use ACE-I/ARB/DRI due to clinically valid reasons. These include renal complications, not having diabetes and/or hypertension, and allergies/intolerances. Clinical interventions focusing on improving this measure should take these situations into account to ensure patients are receiving appropriate medications.

CONCLUSION

- The true impact of the Diabetes Treatment Clinical Program may be affected by the following confounders:
  - Overlapping providers for other members resulting in patients entering the measure as compliant due to the outreach (who otherwise would have entered the measure as non-compliant).
  - Members who received a claim for an ACE-I/ARB/DRI post-outreach who may have received an ACE-I/ARB/DRI regardless.

LIMITATIONS

- Clinical outreach to non-compliant members and their associated providers and pharmacies resulted in a 2-star improvement for the Diabetes Treatment Measure and prevented a 2-star decrease.

- Treatment rate in a health plan utilizing a Diabetes Treatment Clinical Program increased by 4.5% from 2013 to 2014 compared to the national average of 0.8%.

- Many patients did not use ACE-I/ARB/DRI due to clinically valid reasons. These include renal complications, not having diabetes and/or hypertension, and allergies/intolerances. Clinical interventions focusing on improving this measure should take these situations into account to ensure patients are receiving appropriate medications.

REFERENCES


DISCLOSURES

- This research was conducted by Magellan Rx Management, Newport, RI, without external funding.